

NHS Foundation Trust

Document Type:	Unique Identifier:	
Guideline	SCG/011	
Document Title:	Version Number:	
	2.1	
Hydroxycarbamide (Hydroxyurea) for		
Haematological Conditions – Shared Care	Status:	
Guideline	Ratified	
Scope:	Classification:	
Relevant to all staff	Organisational	
Author / Title:	Responsibility:	
Area Prescribing Committees	Pharmacy	
(UHMB contact: Andrea Scott, Pharmacy)		
Replaces:	Head of Department:	
Version 2, Hydroxycarbamide (Hydroxyurea) fo	or Kam Mom, Trust Chief Pharmacist	
Haematological Conditions – Shared Care Guid SCG/011	deline,	
Validated By:	Date:	
Lancs N Area Prescribing Committee	13/12/2016	
Ratified By:	Date:	
Cumbria Area Prescribing Committee	15/12/2016	
Review dates may alter if any significant cha	<u> </u>	
are made	01/12/2019 (Extended – Form	
MILL D. C. C. MILO O. C. C.	052/2018)	
Which Principles of the NHS Constitution	Which Staff Pledges of the NHS	
Apply? Please list from principles 1-7 which apply	Constitution Apply? Please list from staff pledges 1-7 which apply	
<u>Principles</u>	Staff Pledges	
Does this document meet the requirements of t		

Does this document meet the requirements of the Equality Act 2010 in relation to Race, Religion and Belief, Age, Disability, Gender, Sexual Orientation, Gender Identity, Pregnancy & Maternity, Marriage and Civil Partnership, Carers, Human Rights and Social Economic Deprivation discrimination? *Yes / No * Please delete as required

Document for Public Display:	*Yes / No * Please delete as required


Evidence Search Completed by......Not Applicable.....

To be completed by Library and Knowledge Services Staff









SHARED CARE GUIDELINE

Drug: HYDROXYCARBAMIDE (Hydroxyurea) for Haematological Conditions

Introduction	Indication: Used for the management of haematological myeloproliferative disorders including:	
	Essential thrombocythaemia	
	Chronic myeloid leukaemia	
	 Primary proliferative polycythaemia (polycythaemia vera) 	
	Myelofibrosis	
	Unclassified myeloproliferative disorders	
Secondary Care Responsibilities	 Initiate the hydroxycarbamide treatment, and advise the GP (in writing) of any dose modifications required. 	
	2. Arrange shared care with patient's GP after 6 weeks.	
	Provide patient/carer with relevant written information on use, side effects and need for monitoring of medication.	
	4. Provide chemotherapy record booklet for recording of monitoring and information.	
	5. Baseline tests: FBC, LFT, U&E.	
	6. Review results of safety monitoring and request additional tests as required.	
	7. Disease monitoring – response to treatment and need to continue therapy.	
	 Continue to review the patient at agreed specified intervals, sending a written summary to the GP whenever the patient is reviewed, including the current dose to be prescribed. 	
	9. Provide any other advice or information for the GP if required.	
Primary Care Responsibilities	Prescribe hydroxycarbamide as per the written dosage supplied by the hospital specialist.	
	Arrange and record ongoing monitoring as agreed with specialist (some specialists may choose to arrange their own monitoring instead).	
	Identify and report adverse events to the specialist and the MHRA.	
	4. Ensure no drug interactions with other medicines.	
	5. Administer influenza vaccine annually.	
	Check the patient as had one dose of pneumococcal vaccine (re-vaccination is not recommended) – see BNF.	
	 Passive immunization using Varicella-Zoster immunoglobulin (VZIG) should be considered in non-immune patients if exposed to chickenpox or shingles. Contact virology for advice if exposure is suspected. 	
	Ask about oral ulceration/sore throats or unusual bruising at every consultation. If present, arrange urgent FBC.	

Date Prepared: November 2016 Date of Review: December 2019

Monitoring Required in	 FBC – weekly for 6 weeks, reduce to a minimum of once every 3 months for the duration of therapy (in line with advice from specialist) 		
Primary Care	 If MCV > 105fl – B₁₂ and folate should be checked 		
	Results should be recorded in patient's Chemotherapy Book		
	Results should be recorded in patient's Chemotherapy Book		
	Urgently contact the specialist if (if unable to contact the specialist advise the patient to withhold treatment):		
	Hb decreases by 3g/dL		
	WCC < 4 x 10 ⁹ /L		
	Neutrophils < 1 x 10 ⁹ /L		
	Platelets < 100 x 10 ⁹ /L		
Adverse Effects	Leucopenia, anaemia and thrombocytopenia: GPs should be alert to any unexplained bruising or bleeding. Macrocytosis occurs in almost all patients and may persist for up to one year after stopping therapy.		
	Rarely: anorexia, nausea, vomiting, diarrhoea, headache, drowsiness, dizziness, cutaneous hyperpigmentation. If severe or persistent, refer to hospital.		
	Renal dysfunction: hydroxycarbamide should be used with caution in patients with marked renal dysfunction.		
Common Drug Interactions	No significant drug interactions. Toxicity may be potentiated by previous or concomitant radiotherapy or cytotoxic therapy. Patients should not be receiving anti-retroviral therapy containing didanosine and/or stavudine.		
Cautions & Contra- indications	Pregnancy/contraception: female patients must be advised not to conceive whilst receiving hydroxycarbamide. A reliable form of contraception should be used by men and women whilst on hydroxycarbamide.		
	Breastfeeding: women should not breastfeed whilst receiving hydroxycarbamide.		
	Live vaccines should be avoided by patients receiving hydroxycarbamide.		

Protocols on the use of hydroxycarbamide in the treatment of myeloproliferative disorders may be obtained from:

North: ■ http://www.nescn.nhs.uk/wp-content/uploads/2012/12/Hydroxycarbamide-NECN-protocol-CRP08-H0092.pdf

2 (01228) 814563

South: http://www.nwcscnsenate.nhs.uk/files/5414/7453/7623/Haem_Hydroxycarbamide_2.pdf

(01524) 516202 and 07920027896

This guidance does not replace the SPC's, which should be read in conjunction with this guidance.

Date Prepared: November 2016 Date of Review: December 2019